Alexander Drilon MD

Chief, Early Drug Development Service; Associate Attending Physician, Thoracic Oncology Service; Memorial Sloan Kettering Cancer Center

[Alexander Drilon MD @alexdrilon]

@Sandra_Misale @DavidHongMD Great seeing you - the king of many additional kingdoms!!

[Alexander Drilon MD @alexdrilon]

In the era of Project Optimus, expeditiousness needs to be preserved for dose finding in rare cancers. Common cancers now contain multiple rare genomic and proteomic subsets, underscoring the importance of this mindset. @YoninaMG @AlexiaIasonos

[Elizabeth McKenna @ElizSMcKenna]

Now online in @CD_AACR, a special commentary for #ASCO24: Optimus-Era Dose Finding for Rare Cancers - by @YoninaMG, Sean Devlin, @AlexiaIasonos, and @alexdrilon https://t.co/FygmyVUjnY @MSKCancerCenter

[Alexander Drilon MD @alexdrilon]

Repotrectinib is FDA approved for ROS1+ lung cancers in the TKI naive and pretreated settings. Many thanks to the patients, advocates, and study teams around the world who made this possible. https://t.co/gGOxMmswtf

[Sandra Misale @Sandra_Misale]

Two research technician positions are immediately available in my lab @HopkinsMedicine @hopkinskimmel. You will be working on KRAS targeting in solid cancer. If interested, please apply here:
https://t.co/DbToAS15cw

https://t.co/3YKiHIWS7s

[Alexander Drilon MD @alexdrilon]

Don’t miss out on the opportunity to join the lab of the fabulous Dr. Misale. Our phase I team is absolutely excited to continue working with her. Congratulations @Sandra_Misale!!

[Sandra Misale @Sandra_Misale]

I have some news, I'm thrilled to announce that the Misale Lab will open in July at @hopkinskimmel @HopkinsMedicine! We will work on resistance to therapy in solid tumors and we are hiring. Join us in this journey! #newPI #LabLaunch #cancer #kras #targetedtherapies #WomenInSTEM

[Alexander Drilon MD @alexdrilon]

@AhernandoCalvo @CD_AACR @ASCO @MSKCancerCenter Thanks for such a great spotlight!

[Alexander Drilon MD @alexdrilon]

Breaking tradition can improve patient outcomes. In novel-known combinations where the novel drug is unlikely to work well alone, prolonged exposure to monotherapy in dose escalation is not patient-centric. This alternative FDA-approved phase I design poses a potential solution.

[Cancer Discovery @CD_AACR]

Just published: #SHP2 Inhibition Sensitizes Diverse Oncogene-addicted Solid Tumors to Re-treatment with Targeted Therapy by @alexdrilon S. Michael Rothenberg and colleagues @MSKCancerCenter @PfizerOncMed. https://t.co/Ww9VXcUnFf #ASCO23

[Sandra Misale @Sandra_Misale]

Out today in @CD_AACR our new work where we describe the genetic bases of acquired resistance to EGFR/KRAS G12C dual blockade in colorectal cancer. Here’s the link of the paper https://t.co/0OXSB72rXA and a thread👇:

[Alexander Drilon MD @alexdrilon]

Hello, 3rd ed! The print version is out in a few weeks. The digital version is available now on Kindle and other e-readers. Congratulations to @NouraChoudhury @YoninaMG @NeilVasan and the many contributing authors!! https://t.co/25d7fehfrn

[Alexander Drilon MD @alexdrilon]

@FawziAbuRous Thanks! The medians for larotrecrinib DoR and PFS have not yet been reached. (Median follow up was quoted here instead)

[Lukas Delasos @LukasDelasos]

Aaaaand we're back!! 9 years really flew by since I was last here while working at #MSKCC; now as a #HOfellow @ClevelandClinic. Especially humbled to reconnect with a close friend and AMAZING mentor @alexdrilon at #ASCO22!!

[Alexander Drilon MD @alexdrilon]

@LukasDelasos @ClevelandClinic So great to run into you, Luke. We are incredibly proud of your accomplishments!!

[Alexander Drilon MD @alexdrilon]

Excellent work from the Klebanoff lab on TCR development for an HLA-A*03:01 restricted public neoantigen generated in the context of a PIK3CA H1047L catalytic subunit hotspot mutation. https://t.co/u4hjRAPmEk

[Nature Medicine @NatureMedicine]

A high-throughput platform to find rare #Tcells that recognize shared cancer #neoantigens identifies TCRs specific for a conserved and therapeutically actionable epitope in mutant PIK3CA, a common driver oncogene @KlebanoffLab @MSKCancerCenter @parkerici
https://t.co/JuMcnAQtY4

[Alexander Drilon MD @alexdrilon]

RETi resistance in lung, thyroid & other cancers can be complex. This paper includes insights into the serial kinetics of resistance acquisition, the potential emergence of RET wild type populations & the frequency of polyclonal resistance. Proud to be part of this team!

[Alexander Drilon MD @alexdrilon]

The first publication of larotrectinib in NTRK fusion+ lung cancers alone is out. Beyond the initial systemic & intracranial response gains, the ~35 month median PFS and the ~41 month median OS impress. Wonderful news for patients, advocates, and providers across the world.

[JCO Precision Oncology @JCOPO_ASCO]

.@alexdrilon et al. report on first analysis of the efficacy & safety of larotrectinib in pts with TRK fusion–positive lung cancer from a registrational data set. ORR of 73% ub 15 evaluable pts w OS of 40.7 months. Larotrectinib was well tolerated. https://t.co/HoQ25G6mgw

[Alison Schram @AliSchram]

Quick recap of today's presentation of Zeno in heavily pretreated NRG1+ solid tumors. Efficacy observed across tumor types with ORR of 42% in PDAC. Thanks to @ASCO for the opportunity to present, @GarridoLagunaMD for an excellent discussion, collaborators, and patients. #ASCO2021

[Alison Schram @AliSchram]

I’m honored to be among the #ConquerCancer Grant & Award Class of 2021 (CDA) and 2018 (YIA). Donors make these research opportunities possible. Give to the @ASCO CONQUERS CANCER Fund to help fuel the next generation of researchers https://t.co/zwZIF01Ujp #ASCO21

[Gʀᴇɢᴏʀʏ Rɪᴇʟʏ @RielyMD]

Congratulations to @NouraChoudhury on her @ConquerCancerFd @ASCO Young Investigator Award. I'm lucky to co-mentor her with @HelenaYu923 . She has an interesting trial combining amivantamab and lazertinib in patients with EGFR mutant NSCLC progressing in the CNS (almost open!).

[RETpositive @RETpositive]

RETpositive has officially launched! We are a patient-led coalition formed to advance research on RET+ cancers. Through our partnership with @LUNGevity and a generous donation-matching program, we hope to fund lifesaving research. Join us at https://t.co/XkTH53t2ng #RETcancer

[Alexander Drilon MD @alexdrilon]

Repotrectinib gets Breakthrough Therapy Designation by the US FDA for TKI-naïve ROS1 fusion-positive lung cancers. Congratulations to the TRIDENT-1 investigators and patients. https://t.co/iNeyYviX4U